Autopsy report · NCT03593213

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

“FDA Released Allergan from this post marketing requirement”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 587 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Schizophrenia

Interventions

Cariprazine; Placebo

Participants

587

Sites

97

Countries

Bulgaria, Malaysia, Poland, Puerto Rico, Romania, Serbia, South Korea, Taiwan, Thailand, Ukraine, United States

Trials that died the same way

• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
  “Sponsor decision following FDA release from the PMR.” (58% match in meaning)
• Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
  “The study stopped due to marketing approval by the FDA.” (56% match in meaning)
• Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.
  “No IND submitted to the FDA” (56% match in meaning)
• Electrical Impedence Tomography With ENLIGHT2100
  “Device received FDA approval” (56% match in meaning)
• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.